FREE DOWNLOAD: Lay Summary Whitepaper
This complimentary lay summary whitepaper will explain:
- the ins and outs of lay summary writing,
- the importance of starting a pilot program,
- a checklist for lay reviewers, and
- strategic advice for becoming more transparent.
Click on the image for the full whitepaper.
This whitepaper was authored by Manager of Disclosures Services Kasim McLain, Senior Transparency Lead and Medical Writer Jennifer Pilgrim, and Associate Manager of Corporate Quality Jessica Alamdari.
Suggested For You
perspectives
November 21st, 2024
Essential Nonclinical Strategies for Cell and Gene Therapy (CGT) Success
perspectives
November 12th, 2024
REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar
perspectives
November 6th, 2024
How to Successfully Manage Rescue Studies and Turn Around Clinical Trials Facing Failure
perspectives
October 29th, 2024
Why Outsourcing QC of Regulatory and Medical Writing Documents is a Competitive Advantage for Large Pharma Companies
perspectives
October 22nd, 2024
Choosing the Right Clinical Trial Design: A Crucial Step in Protocol Development
perspectives
October 15th, 2024
Putting the Action in Diversity Action Plans and the Real-Time Data Visualization Technology Needed to Ensure It Happens
perspectives
October 8th, 2024
Diversity Action Plan Guidance Part I: Implications for Sponsors
perspectives
September 30th, 2024
Meet the Leaders Driving MMS’s European Growth
perspectives
September 30th, 2024
The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry
perspectives
September 24th, 2024
Embracing Quality Management Maturity (QMM) at the Cornerstone of the Pharmaceutical Industry
perspectives
September 11th, 2024
From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs
perspectives
September 4th, 2024
Email Security – Navigating Through the Process of Validation and Compliance with Healthcare Business Stakeholders